So, in humongous markets, investors and professionals prefer tiny numbers since they feel more realistic. OK.

So, where did LE get $1 billion as a value for licensing Kevetrin if not through some expectation of humongous market after approval? And, it was his number that spurred my exploration of market potential based on clinical success aligned with animal results.

So, I guess to professionals and investors the numbers that come from recent licenses are not relevant either since they tend to be too big ($3.5 billion for diabetes drugs, and $1.5 billion for breast cancer treatment)? OK, I can see that now. And, when I point out that the global market for prostate cancer is $26 billion and capturing only 5% of that market yields $1.3 billion for only one cancer type against which K should be effective, again that is just too big a number to even consider as realistic since there are so many drugs in clinical trials.

Sorry to rankle the sensibilities of professionals and investors.